Moderna (MRNA) EBIAT: 2017-2025
Historic EBIAT for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$200.0 million.
- Moderna's EBIAT fell 1638.46% to -$200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 billion, marking a year-over-year decrease of 40.11%. This contributed to the annual value of -$3.6 billion for FY2024, which is 24.46% up from last year.
- According to the latest figures from Q3 2025, Moderna's EBIAT is -$200.0 million, which was up 75.76% from -$825.0 million recorded in Q2 2025.
- In the past 5 years, Moderna's EBIAT ranged from a high of $4.9 billion in Q4 2021 and a low of -$3.6 billion during Q3 2023.
- Over the past 3 years, Moderna's median EBIAT value was -$971.0 million (recorded in 2025), while the average stood at -$933.7 million.
- In the last 5 years, Moderna's EBIAT soared by 2,476.07% in 2021 and then slumped by 1,638.46% in 2025.
- Quarterly analysis of 5 years shows Moderna's EBIAT stood at $4.9 billion in 2021, then plummeted by 69.91% to $1.5 billion in 2022, then crashed by 85.19% to $217.0 million in 2023, then slumped by 616.13% to -$1.1 billion in 2024, then slumped by 1,638.46% to -$200.0 million in 2025.
- Its EBIAT was -$200.0 million in Q3 2025, compared to -$825.0 million in Q2 2025 and -$971.0 million in Q1 2025.